Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CIR Panel Grapples With Safety Review Protocol For Nanomaterials

Executive Summary

The Cosmetic Ingredient Review Expert Panel broached the subject of nano-ingredient reviews at its June 12 meeting. The Personal Care Products Council’s Jay Ansell stressed that ingredient safety should continue to be CIR’s chief concern, not whether a material fits any particular “nanotech” designation.

Advertisement

Related Content

In Brief
CIR Releases 2013 Draft Review Priorities For Public Comment
Clinical Studies May Be Needed For Cosmetics With Nanomaterials – FDA
Europe May Reduce Scope Of 2013 Ban On Animal-Tested Cosmetics
FDA Nanotech Guidance Draws Industry Comment On Particle Size Criteria

Topics

Advertisement
UsernamePublicRestriction

Register

RS018143

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel